Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

Kister, Ilya; Spelman, Tim; Patti, Francesco; Duquette, Pierre; Trojano, Maria; Izquierdo, Guillermo; Lugaresi, Alessandra; Grammond, Pierre; Sola, Patrizia; Ferraro, Diana; Grand'Maison, Francois; Alroughani, Raed; TERZİ, MURAT; BOZ, CAVİT; Hupperts, Raymond; Lechner-Scott, Jeannette; Kappos, Ludwig; Pucci, Eugenio; Hodgkinson, Suzanne; Solaro, Claudio; Butzkueven, Helmut

doi:10.1016/j.jns.2018.06.001

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

Copy For Citation

Kister I., Spelman T., Patti F., Duquette P., Trojano M., Izquierdo G., ...More

JOURNAL OF THE NEUROLOGICAL SCIENCES, vol.391, pp.72-76, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 391
Publication Date: 2018
Doi Number: 10.1016/j.jns.2018.06.001
Journal Name: JOURNAL OF THE NEUROLOGICAL SCIENCES
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.72-76
Keywords: Multiple sclerosis, Relapse, Disability, Disease modifying therapy, Observational cohort study, MULTIPLE-SCLEROSIS, FINGOLIMOD TREATMENT, NATALIZUMAB, WITHDRAWAL, CESSATION, COHORT
Karadeniz Technical University Affiliated: Yes

Abstract

Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large global observational registry, affords a unique opportunity to investigate predictors of 'post-DMT' relapses and confirmed disability progression (CDP) in a diverse group of patients exposed to different DMTs.